PDCD1 and neoplasm: As for PD-1/PD-L1 blockade resistance, the constitutive PD-L1 expression in tumor cells as well as the lack of tumor antigens, defective antigen presentation, activation of oncogenic pathways, mutations in interferon gamma signaling and changes in the tumor microenvironment are the most important factors associated with immunotherapy resistance [227].